Guangan Hu

Guangan Hu

Auto-generated profile, based on publicly available information

Guangan Hu

Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Nature Biotechnology
Verified
Journal Article
Closed access
GHGuangan Hu
Guangan Hu
ACAna Cabrera
Ana Cabrera
MKMaya Kono
Maya Kono
SMSachel Mok
Sachel Mok
BCBalbir K Chaal
Balbir K Chaal
ZBZbynek Bozdech
Zbynek Bozdech

21 October 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ZBZbynek Bozdech
Zbynek Bozdech
SMSachel Mok
Sachel Mok
GHGuangan Hu
Guangan Hu
MIMallika Imwong
Mallika Imwong
AJAnchalee Jaidee
Anchalee Jaidee
PPPeter R. Preiser
Peter R. Preiser
Plasmodium vivax causes over 100 million clinical infections each year. Primarily because of the lack of a suitable culture system, our understanding of the biology of this parasite lags significantly behind that of the more deadly species P. falciparum . Here, we present the complete transcriptional profile throughout the 48-h intraerythrocytic cycle of three distinct P. vivax isolates. This approach identifies strain specific patterns of expression for subsets of genes predicted to encode proteins associated with virulence and host pathogen interactions. Comparison to P. falciparum revealed significant differences in the expression of genes involved in crucial cellular functions that underpin the biological differences between the two parasite species. These data provide insights into the biology of P. vivax and constitute an important resource for the development of therapeutic approaches.

1 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RSRoman M. Shapiro
Roman M. Shapiro
GBGrace C. Birch
Grace C. Birch
GHGuangan Hu
Guangan Hu
JCJuliana Vergara Cadavid
Juliana Vergara Cadavid
SNSarah Nikiforow
Sarah Nikiforow
RRRizwan Romee
Rizwan Romee
Background. Responses to conventional donor lymphocyte infusion for postallogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell–based therapy is a promising modality to treat post-HCT relapse. Methods. We initiated this ongoing phase I trial of adoptively transferred cytokine-induced memory-like (CIML) NK cells in patients with myeloid malignancies who relapsed after haploidentical HCT. All patients received a donor-derived NK cell dose of 5 to 10 million cells/kg after lymphodepleting chemotherapy, followed by systemic IL-2 for 7 doses. High-resolution profiling with mass cytometry and single-cell RNA sequencing characterized the expanding and persistent NK cell subpopulations in a longitudinal manner after infusion. Results. In the first 6 enrolled patients on the trial, infusion of CIML NK cells led to a rapid 10- to 50-fold in vivo expansion that was sustained over months. The infusion was well tolerated, with fever and pancytopenia as the most common adverse events. Expansion of NK cells was distinct from IL-2 effects on endogenous post-HCT NK cells, and not dependent on CMV viremia. Immunophenotypic and transcriptional profiling revealed a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires. Conclusion. Given their rapid expansion and long-term persistence in an immune-compatible environment, CIML NK cells serve as a promising platform for the treatment of posttransplant relapse of myeloid disease. Further characterization of their unique in vivo biology and interaction with both T cells and tumor targets will lead to improvements in cell-based immunotherapies. Trial Registration. ClinicalTrials.gov NCT04024761. Funding. Dunkin’ Donuts, NIH/National Cancer Institute, and the Leukemia and Lymphoma Society.

3 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGuangan Hu
Guangan Hu
YSYang Su
Yang Su
BKByong Ha Kang
Byong Ha Kang
ZFZhongqi Fan
Zhongqi Fan
TDTing Dong
Ting Dong
JCJianzhu Chen
Jianzhu Chen
Macrophages are plastic and, in response to different local stimuli, can polarize toward multi-dimensional spectrum of phenotypes, including the pro-inflammatory M1-like and the anti-inflammatory M2-like states. Using a high-throughput phenotypic screen in a library of ~4000 FDA-approved drugs, bioactive compounds and natural products, we find ~300 compounds that potently activate primary human macrophages toward either M1-like or M2-like state, of which ~30 are capable of reprogramming M1-like macrophages toward M2-like state and another ~20 for the reverse repolarization. Transcriptional analyses of macrophages treated with 34 non-redundant compounds identify both shared and unique targets and pathways through which the tested compounds modulate macrophage activation. One M1-activating compound, thiostrepton, is able to reprogram tumor-associated macrophages toward M1-like state in mice, and exhibit potent anti-tumor activity. Our compound-screening results thus help to provide a valuable resource not only for studying the macrophage biology but also for developing therapeutics through modulating macrophage activation.

12 December 2013 in Nature Communications
Verified
Journal Article
Closed access
PDF file
GHGuangan Hu
Guangan Hu
JCJianzhu Chen
Jianzhu Chen

1 May 2016 in EBioMedicine
Verified
Journal Article
Open access
RHRegina Hoo
Regina Hoo
LZLei Zhu
Lei Zhu
AAAnburaj Amaladoss
Anburaj Amaladoss
SMSachel Mok
Sachel Mok
ONOnguma Natalang
Onguma Natalang
PPPeter R. Preiser
Peter R. Preiser
The genome sequence available for different Plasmodium species is a valuable resource for understanding malaria parasite biology. However, comparative genomics on its own cannot fully explain all the species-specific differences which suggests that other genomic aspects such as regulation of gene expression play an important role in defining species-specific characteristics. Here, we developed a comprehensive approach to measure transcriptional changes of the evolutionary conserved syntenic orthologs during the intraerythrocytic developmental cycle across six Plasmodium species. We show significant transcriptional constraint at the mid-developmental stage of Plasmodium species while the earliest stages of parasite development display the greatest transcriptional variation associated with critical functional processes. Modeling of the evolutionary relationship based on changes in transcriptional profile reveal a phylogeny pattern of the Plasmodium species that strictly follows its mammalian hosts. In addition, the work shows that transcriptional conserved orthologs represent potential future targets for anti-malaria intervention as they would be expected to carry out key essential functions within the parasites. This work provides an integrated analysis of orthologous transcriptome, which aims to provide insights into the Plasmodium evolution thereby establishing a framework to explore complex pathways and drug discovery in Plasmodium species with broad host range.